Pages that link to "Q35040841"
Jump to navigation
Jump to search
The following pages link to Anti-idiotype antibody vaccine therapy for cancer (Q35040841):
Displaying 17 items.
- Cancer vaccines: state of the art of the computational modeling approaches (Q26825044) (← links)
- Development of a phage displayed disulfide-stabilized Fv fragment vaccine against Vibrio anguillarum (Q31160872) (← links)
- A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. (Q33467203) (← links)
- Generation of anti-idiotype scFv for pharmacokinetic measurement in lymphoma patients treated with chimera anti-CD22 antibody SM03. (Q33590238) (← links)
- Strategies in cancer vaccines development (Q35143294) (← links)
- Ongoing and future trials of biologic therapies in lung cancer. (Q35179468) (← links)
- Abagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer (Q35564007) (← links)
- Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma (Q35953824) (← links)
- Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view. (Q36063243) (← links)
- Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. (Q36235000) (← links)
- Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins (Q36386109) (← links)
- Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate (Q36786062) (← links)
- Anti-idiotype antibodies in cancer treatment (Q36832098) (← links)
- Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. (Q39165145) (← links)
- Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen (Q40245988) (← links)
- Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study (Q43793343) (← links)
- scFv6.C4 DNA vaccine with fragment C of tetanus toxin increases protective immunity against CEA-expressing tumor (Q96126755) (← links)